Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria children by retroviral-mediated gene transfer

被引:16
作者
Lin, CM
Tan, Y
Lee, YM
Chang, CC
Hsiao, KJ
机构
[1] NATL YANG MING UNIV, INST GENET, TAIPEI 112, TAIWAN
[2] VET GEN HOSP, DEPT MED RES, TAIPEI 11217, TAIWAN
关键词
D O I
10.1023/A:1005303331218
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Classical phenylketonuria (PKU) is a metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene. At present, T lymphocyte directed gene therapy is the only means for which a safety record has been established. Thus. we investigated the applicability of this strategy to PKU gene therapy. We first looked for tetrahydrobiopterin (BH4) and dihydropteridine reductase (DHPR) activity, which are required for the phenylalanine hydroxylation reaction and BH4 regeneration, respectively, in T cells isolated from PKU children, We found that T cells contained a small amount of biopterin, but significant DHPR activity. and that the intracellular biopterin content could be increased by exogenous BH4 supplementation. Moreover, PKU T cells were capable of taking up phenylalanine efficiently and effluxing acquired tyrosine. Finally, a recombinant retrovirus contailling the human PAH cDNA was constructed and used to transduce isolated PKU T cells. Viral-transduced T cells produced high levels of PAH activity as compared to control mock-infected T cells. These results indicate that T lymphocytes express ail that is required for synthesizing/replenishing constituents of the phenylalanine hydroxylation reaction and expressing transduced phenylalanine hydroxylase cDNA.
引用
收藏
页码:742 / 754
页数:13
相关论文
共 47 条
[1]  
BARTHOLOME K, 1979, HUM GENET, V51, P241
[2]   T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS [J].
BLAESE, RM ;
CULVER, KW ;
MILLER, AD ;
CARTER, CS ;
FLEISHER, T ;
CLERICI, M ;
SHEARER, G ;
CHANG, L ;
CHIANG, YW ;
TOLSTOSHEV, P ;
GREENBLATT, JJ ;
ROSENBERG, SA ;
KLEIN, H ;
BERGER, M ;
MULLEN, CA ;
RAMSEY, WJ ;
MUUL, L ;
MORGAN, RA ;
ANDERSON, WF .
SCIENCE, 1995, 270 (5235) :475-480
[3]  
BLAU N, 1988, ANNU REV NUTR, V8, P185
[4]   GENE-THERAPY IN PERIPHERAL-BLOOD LYMPHOCYTES AND BONE-MARROW FOR ADA(-) IMMUNODEFICIENT PATIENTS [J].
BORDIGNON, C ;
NOTARANGELO, LD ;
NOBILI, N ;
FERRARI, G ;
CASORATI, G ;
PANINA, P ;
MAZZOLARI, E ;
MAGGIONI, D ;
ROSSI, C ;
SERVIDA, P ;
UGAZIO, AG ;
MAVILIO, F .
SCIENCE, 1995, 270 (5235) :470-475
[5]   Preclinical studies of lymphocyte gene therapy for mild Hunter syndrome (mucopolysaccharidosis type II) [J].
Braun, SE ;
Pan, D ;
Aronovich, EL ;
Jonsson, JJ ;
McIvor, RS ;
Whitley, CB .
HUMAN GENE THERAPY, 1996, 7 (03) :283-290
[6]  
BROXMEYER HE, 1992, CURR TOP MICROBIOL, V177, P195
[7]   HIGH-EFFICIENCY RETROVIRAL-MEDIATED GENE-TRANSFER INTO HUMAN AND NONHUMAN PRIMATE PERIPHERAL-BLOOD LYMPHOCYTES [J].
BUNNELL, BA ;
MUUL, LM ;
DONAHUE, RE ;
BLAESE, RM ;
MORGAN, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) :7739-7743
[8]  
Byun J, 1996, GENE THER, V3, P780
[9]  
CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351
[10]   Somatic gene therapy for phenylketonuria and other hepatic deficiencies [J].
Eisensmith, RC ;
Woo, SLC .
JOURNAL OF INHERITED METABOLIC DISEASE, 1996, 19 (04) :412-423